# Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.

> **NCT02560337** · PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 26 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Cabazitaxel

## Key facts

- **NCT ID:** NCT02560337
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-12-05
- **Final completion:** 2019-06-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560337, "Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02560337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*